Correspondence 0001193125-25-021280 from Kalaris Therapeutics, Inc. (KLRS)
Kalaris Therapeutics, Inc.
Date: Feb. 6, 2025 · CIK: 0001754068 · Accession: 0001193125-25-021280
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283678
Letter
VIA EDGAR Office of Life Sciences Division of Corporation Finance Attention: Requested Date: February 10, 2025 Requested Time: 8:00 a.m. Eastern Time
Dear Mr. Crawford, Mr. Buchmiller, Ms. Ignat and Mr. Gordon:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), AlloVir, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to February 10, 2025, at 8:00 a.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Tevia K. Pollard at (617) 570-1084. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Tevia K. Pollard, by email to TPollard@goodwinlaw.com or by facsimile to (617) 977-9448.
If you have any questions regarding this request, please contact Tevia K. Pollard of Goodwin Procter LLP at (617) 570-1084.
Sincerely,
AlloVir, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP AlloVir, Inc. PO Box 44, 1661 Massachusetts Avenue Lexington, MA 02420 February 6, 2025 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street NE Washington, DC 20549 Attention: Mr. Daniel Crawford Mr. Tim Buchmiller Ms. Ibolya Ignat Mr. Daniel Gordon Re: AlloVir, Inc. Acceleration Request for Registration Statement on Form S-4 File No. 333-283678 Requested Date: February 10, 2025 Requested Time: 8:00 a.m. Eastern Time Dear Mr. Crawford, Mr. Buchmiller, Ms. Ignat and Mr. Gordon: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), AlloVir, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to February 10, 2025, at 8:00 a.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Tevia K. Pollard at (617) 570-1084. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Tevia K. Pollard, by email to TPollard@goodwinlaw.com or by facsimile to (617) 977-9448. If you have any questions regarding this request, please contact Tevia K. Pollard of Goodwin Procter LLP at (617) 570-1084. Sincerely, AlloVir, Inc. By: /s/ Vikas Sinha Vikas Sinha Chief Executive Officer, President and Chief Financial Officer cc: Tevia K. Pollard, Goodwin Procter LLP Danielle Lauzon, Goodwin Procter LLP